The U.S. Food and Drug Administration today approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium ...

Patients with nontuberculous mycobacterial pulmonary disease caused by Mycobacterium avium complex had significantly improved survival if they achieved microbiological cure at the end of treatment, ...

DRESHER, PA. (WPVI) -- We need bacteria to digest food and absorb nutrients. However, when a bacteria commonly found in soil and water gets into our lungs, it can cause trouble, in the form of a MAC ...

Please provide your email address to receive an email when new articles are posted on . Nearly half of patients reported improvements to quality of life compared with placebo. Nontuberculous ...

The FDA established the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) as part of the 21st Century Cures Act that was signed into law in December 2016. The LPAD ...

The first drug specifically to treat patients with Mycobacterium avium complex, a rare and chronic lung disease, has been approved by the FDA. Arikayce is also the first drug to be approved under the ...